Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

26.42USD
26 Jun 2017
Change (% chg)

-- (--)
Prev Close
$26.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
399,808
52-wk High
$32.56
52-wk Low
$15.15

MYGN.OQ

Chart for MYGN.OQ

About

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)

Overall

Beta: 0.38
Market Cap(Mil.): $1,799.69
Shares Outstanding(Mil.): 68.12
Dividend: --
Yield (%): --

Financials

  MYGN.OQ Industry Sector
P/E (TTM): 43.11 39.14 19.01
EPS (TTM): 0.61 -- --
ROI: 4.83 8.76 -5.03
ROE: 5.87 13.54 -4.28

BRIEF-Agena Bioscience announces expanded partnership with Assurex Health

* Agena bioscience - assurex health, subsidiary of myriad genetics, has selected massarray system for streamlined laboratory set-up, sample processing of assurex health's genesight test

Jun 20 2017

BRIEF-Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

* Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

Jun 02 2017

BRIEF-Myriad Genetics announced new data "demonstrating utility" of prolaris test

* Myriad Genetics - announced new data "demonstrating utility" of prolaris test to predict 10-year risk of metastases in men treated for prostate cancer Source text for Eikon: Further company coverage:

May 12 2017

BRIEF-Myriad Genetics reports Q3 adj earnings per share $0.27

* Myriad Genetics reports fiscal third-quarter 2017 financial results

May 02 2017

BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test

* Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment

Apr 27 2017

BRIEF-Myriad Genetics, Beigene sign agreement

* Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290

Apr 06 2017

BRIEF-Myriad Genetics launches the endopredict test in U.S for patients with breast cancer

* Myriad Genetics launches the endopredict test in the United States for patients with breast cancer Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-D. E. Shaw & CO reports 5 pct passive stake in Myriad Genetics -SEC filing

* D. E. Shaw & CO, L.P. Reports a 5 percent passive stake in Myriad Genetics Inc as of February 22, 2017-sec filing Source text for Eikon: Further company coverage:

Mar 06 2017

BRIEF-Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23

* Myriad Genetics Inc director John Henderson reports purchase of 6,000 shares of co's common stock on Feb 22-23 - SEC filing Source text: (http://bit.ly/2mpiARG) Further company coverage:

Feb 23 2017

BRIEF-D. E. Shaw reports 5 pct passive stake in Myriad Genetics

* D. E. Shaw & Co., L.P. reports 5 pct passive stake in Myriad Genetics Inc as of Feb 9 - SEC filing Source text: (http://bit.ly/2lDFO9O) Further company coverage:

Feb 21 2017

More From Around the Web

Earnings vs. Estimates